{Reference Type}: Journal Article
{Title}: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
{Author}: Bozonnat A;Beylot-Barry M;Dereure O;D'Incan M;Quereux G;Guenova E;Perier-Muzet M;Dalle S;Grange F;Viguier MA;Ram-Wolff C;Feldmeyer L;Beltraminelli H;Bonnet N;Amatore F;Maubec E;Franck N;Machet L;Chasset F;Brunet-Possenti F;Bouaziz JD;Battistella M;Donzel M;Pham-Ledard A;Bejar C;Moins-Teisserenc H;Mourah S;Saiag P;Hainaut E;Michel C;Bens G;Adamski H;Aubin F;Boulinguez S;Joly P;Tedbirt B;Templier I;Troin L;Montaudié H;Ingen-Housz-Oro S;Faiz S;Mortier L;Dobos G;Bagot M;Resche-Rigon M;Montlahuc C;Serret-Larmande A;de Masson A; ;
{Journal}: EClinicalMedicine
{Volume}: 73
{Issue}: 0
{Year}: 2024 Jul
{Factor}: 17.033
{DOI}: 10.1016/j.eclinm.2024.102679
{Abstract}: <B>UNASSIGNED: </B>Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.<BR><B>UNASSIGNED: </B>Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registered in ClinicalTrials (SURPASSe01 study: NCT05206045).<BR><B>UNASSIGNED: </B>Three hundred and thirty-nine patients were included (58% men, median age at diagnosis of 70 years, Q1-Q3, 61-79): 33 pre-Sézary (9.7% of 339), 296 Sézary syndrome (87.3%), of whom 10 (2.9%) had large-cell transformation. One hundred and ten patients received mogamulizumab. Median follow-up was 58 months (95% confidence interval [CI], 53-68). OS was 46.5% (95% CI, 40.6%-53.3%) at 5 years. Multivariable analysis showed that age ≥ 80 versus <50 (HR: 4.9, 95% CI, 2.1-11.2, p = 0.001), and large-cell transformation (HR: 2.8, 95% CI, 1.6-5.1, p = 0.001) were independent and significant factors associated with reduced OS. Mogamulizumab treatment was significantly associated with decreased mortality (HR: 0.34, 95% CI, 0.15-0.80, p = 0.013).<BR><B>UNASSIGNED: </B>Treatment with mogamulizumab was significantly and independently associated with decreased mortality in Sézary syndrome.<BR><B>UNASSIGNED: </B>French Society of Dermatology, Swiss National Science Foundation (IZLIZ3_200253/1) and SKINTEGRITY.CH collaborative research program.